Fig. 1.
M100907 and pimavanserin suppress target premature responses in the 1-CSRT task. The effects of M100907 (0.001, 0.01, and 0.1 mg/kg; n = 11) or pimavanserin (0.3, 1, 3 mg/kg; n = 9) were each evaluated under an ITI5 schedule in the 1-CSRT task. (A) M100907 significantly decreased target premature responses at 0.1 mg/kg (*P < 0.05 vs. VEH). (B) Pimavanserin significantly decreased target premature responses at 0.3, 1, and 3 mg/kg (*P < 0.05 vs. VEH).